Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Glycemic Outcomes in Baseline Hemoglobin A1C Subgroups in the International Diabetes Closed-Loop (iDCL) Trial. Diabetes technology & therapeutics Ekhlaspour, L., Town, M. A., Raghinaru, D., Lum, J., Brown, S., Buckingham, B. A. 2022

Abstract

Using a closed-loop system significantly improves time in range 70-180 mg/dL (TIR) in patients with type 1 Diabetes (T1D). In a 6-month RCT, 112 subjects were randomly assigned to closed-loop control (CLC, Tandem Control-IQ) after obtaining two weeks of baseline CGM data from sensor-augmented pump therapy. We compared glycemic outcomes from baseline to end of study among subgroups classified by baseline HbA1c levels. All HbA1c subgroups showed an improvement in TIR due to reduction of both hyperglycemia and hypoglycemia. Those with HbA1c <6.5% improved mostly by reducing nocturnal hypoglycemia due to the automated basal insulin adjustments. Those with HbA1c =8.5% improved mostly by reducing daytime and nocturnal hyperglycemia due to both automated basal insulin adjustments and correction boluses during the day. There does not appear to be any reason to exclude individuals with T1D from automated insulin delivery based on their HbA1c.

View details for DOI 10.1089/dia.2021.0524

View details for PubMedID 35020488